Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment

Core Insights - Limaca Medical Ltd.'s Precision-GI™ motorized endoscopic biopsy device has received transitional pass-through (TPT) payment approval from the Centers for Medicare & Medicaid Services (CMS), enhancing patient access to this innovative technology starting January 1, 2025 [1][2] - The Precision-GI™ device aims to improve biopsy results for patients with suspected gastrointestinal cancers, including pancreatic and liver cancers, and has previously received FDA Breakthrough Device Designation and clearance [1][2] Company Overview - Limaca Medical is an Israel-based company focused on enhancing endoscopic biopsy results for patients with potentially life-threatening cancers, supported by various investors including the Israeli Innovation Authority and The Trendlines Group [5] - The company is also pursuing market entry in Japan in collaboration with HekaBio [4][5] Product Details - The Precision-GI™ device features a motorized, automated, rotating cutting mechanism that allows for superior tissue acquisition quality, reducing blood content and procedure time compared to traditional endoscopic biopsy devices [3] - The device has begun its U.S. market entry after performing its first cases in September 2024, addressing the significant global incidence of pancreatic cancer, which recorded 510,992 new cases in 2022 [4]